Auzzi Shopping

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

  • Written by Auzzi Shopping
  • 87% of respondents deemed mRNA a key modality for the future
  • More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
  • Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption

SINGAPORE - Media OutReach - 31 May 2023 - According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a "game-changer" for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

Filling of Merck
Filling of Merck's synthetic cholesterol, a key component of mRNA-based vaccines and therapeutics, at the company's Darmstadt facility

"Vaccine manufacturers in APAC are looking to build capacity for mRNA technology over the next two to three years, while continuing to produce both traditional and modern cell-based vaccines," said Josephine Cheng, Senior Consultant, Process Solutions APAC at the Life Science business sector of Merck. "Across APAC, governments are investing and supportive of driving therapeutic discovery and manufacturing. With the range of tools we offer, we can better equip vaccine manufacturers to treat the regional and global population."

The study interviewed vaccine manufacturers across APAC, including research institutes, pharmaceutical and biotech companies. Eighty-seven percent deemed mRNA a promising technology, expecting it to be a key modality in the future. This is based on the perception that the mRNA platform benefits from shorter development time and templated manufacturing processes, proven efficacy, lower biohazard risk for operators, and flexibility in covering different types of diseases and variants.

Japan, South Korea, Australia, Indonesia, Singapore, China and India are among the markets actively exploring to develop mRNA technology. Over sixty percent of the vaccine makers prefer to revamp or establish new facilities especially for mRNA with expansion planned over the next two to three years.

To effectively move mRNA forward, respondents highlighted the need for skilled personnel trained in these new technologies, tech-transfer expertise, a reliable supply chain, and mRNA-specific regulatory guidelines.

Merck’s contribution to future vaccine manufacturing
Merck's Life Science business supports mRNA manufacturers helping accelerate speed to market, ensuring safety and efficacy, to reducing complexity across the entire mRNA process to help accelerate delivery of mRNA vaccines to patients worldwide. More information is available on sigmaaldrich.com/vaccines
Hashtag: #Merck

The issuer is solely responsible for the content of this announcement.

Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.

Today's Features at Auzzi

How to Choose Budget-Friendly Artificial Grass Without Compromising Quality

It can be quite a tough task to choose affordable artificial turf that does not compromise on quality. However, if one knows what makes artificial turf appealing and long-lasting it might ...

Bathroom Renovations in Bentleigh: Transform Your Space with Style and Functionality

Bathrooms are the centre of the home, the most trafficked area, and determine property value. Every day the trends of the buildings are changing in Bentleigh. People are opting every day t...

Why You Should Hire a Local Moving Company for a Smooth Move

Moving to another state is exciting but it can also be stressful. You have to pack, organise and transport all your stuff safely. Without the right help, it can quickly become overwhelming...

From Baseball Caps to Beanies: The Best Promotional Headwear in Australia

Promotional headwear is a versatile and effective way for Australian businesses to boost brand visibility. From classic baseball caps to trendy beanies, headwear items can be customised to...

Breaking the Cycle: Holistic Approaches to Managing Mental Health Challenges

Many people today are reeling from stress and exhaustion in their day-to-day lives. They are either sad, scared, or worried about their present and the future. These people may experience ...

What is a Pulse Oximeter and How Does it Work?

The pulse oximeter has almost become a household name. It rose to the limelight back in 2020 during the peak of the COVID-19 pandemic. People were buying them for at-home monitoring to ke...

Discovering Australian-inspired wall art

In the world of interior design, wall art has always played a pivotal role in setting the tone of a space. Australian-inspired wall art, in particular, has gained traction for its unique a...